Construction and analysis of variants of a polyvalent Lyme disease vaccine: Approaches for improving the immune response to chimeric vaccinogens

Vaccine

Volumn 25, Issue 17, 2007, Pages 3419-3427

  Earnhart, Christopher G ^a   Marconi, Richard T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borrelia burgdorferi; Lyme disease vaccine; Outer surface protein C

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; ARGININE; BACTERIAL PROTEIN; EPITOPE; FREUND ADJUVANT; GLUTAMIC ACID; IMMUNOGLOBULIN G; LYME DISEASE VACCINE; OUTER SURFACE PROTEIN C; OUTER SURFACE PROTEIN C ABKD; OUTER SURFACE PROTEIN C ABKDD; OUTER SURFACE PROTEIN C ADBKD; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; DIALYSIS; DRUG SOLUBILITY; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BASE SEQUENCE; IMMUNOGLOBULIN G; LYME DISEASE VACCINES; MALE; MICE; MICE, INBRED C3H; MOLECULAR SEQUENCE DATA; VACCINES, SYNTHETIC;

EID: 34047168361     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.051     Document Type: Article

References (58)

1. Burgdorfer W., Barbour A.G., Hayes S.F., Benach J.L., Grunwaldt E., and Davis J.P. Lyme disease-a tick-borne spirochetosis?. Science 216 (1982) 1317-1319
2. Benach J.L., Bosler E.M., Hanrahan J.P., Coleman J.L., Habicht G.S., Bast T.F., et al. Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med 308 13 (1983) 740-742
3. Steere A.C., and Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 4 2 (2004) 143-152
4. Steere A.C., Malawista S.E., Snydman D.R., Shope R.E., Andiman W.A., Ross M.R., et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 20 1 (1977) 7-17
5. Eiffert H., Karsten A., Thomssen R., and Christen H.J. Characterization of Borrelia burgdorferi strains in Lyme arthritis. Scand J Infect Dis 30 3 (1998) 265-268
6. Asch E.S., Bujak D.I., Weiss M., Peterson M.G., and Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 21 3 (1994) 454-461
7. Nagi K.S., Joshi R., and Thakur R.K. Cardiac manifestations of Lyme disease: a review. Can J Cardiol 12 5 (1996) 503-506
8. Barthold S.W., Persing D.H., Armstrong A.L., and Peeples R.A. Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice. Am J Pathol 139 2 (1991) 263-273
9. Nachman S.A., and Pontrelli L. Central nervous system Lyme disease. Semin Pediatr Infect Dis 14 2 (2003) 123-130
10. Coyle P.K., and Schutzer S.E. Neurologic aspects of Lyme disease. Med Clin North Am 86 2 (2002) 261-284
11. Meltzer M.I., Dennis D.T., and Orloski K.A. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 5 3 (1999) 321-328
12. Shadick N.A., Liang M.H., Phillips C.B., Fossel K., and Kuntz K.M. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 161 4 (2001) 554-561
13. Kalish R.A., Leong J.M., and Steere A.C. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 61 7 (1993) 2774-2779
14. Brown E.L., Kim J.H., Reisenbichler E.S., and Hook M. Multicomponent Lyme vaccine: three is not a crowd. Vaccine 23 28 (2005) 3687-3696
15. Scheiblhofer S., Weiss R., Durnberger H., Mostbock S., Breitenbach M., Livey I., et al. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes Infect 5 11 (2003) 939-946
16. Wallich R., Siebers A., Jahraus O., Brenner C., Stehle T., and Simon M.M. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but not for resolution of Lyme disease. Infect Immun 69 4 (2001) 2130-2136
17. Earnhart C.G., Buckles E.L., and Marconi R.T. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 25 3 (2007) 466-480
18. Schwan T.G. Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi. Biochem Soc Trans 31 Pt 1 (2003) 108-112
19. Gilmore Jr. R.D., Mbow M.L., and Stevenson B. Analysis of Borrelia burgdorferi gene expression during life cycle phases of the tick vector Ixodes scapularis. Microbes Infect 3 10 (2001) 799-808
20. Schwan T.G., Piesman J., Golde W.T., Dolan M.C., and Rosa P.A. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci USA 92 7 (1995) 2909-2913
21. Gilmore Jr. R.D., Kappel K.J., Dolan M.C., Burkot T.R., and Johnson B.J. Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun 64 6 (1996) 2234-2239
22. Bockenstedt L.K., Hodzic E., Feng S., Bourrel K.W., de Silva A., Montgomery R.R., et al. Borrelia burgdorferi strain-specific OspC mediated immunity in mice. Infect Immun 65 (1997) 4661-4667
23. Gilmore Jr. R.D., and Mbow M.L. Conformational nature of the Borrelia burgdorferi B31 outer surface protein C protective epitope. Infect Immun 67 10 (1999) 5463-5469
24. Mathiesen M.J., Holm A., Christiansen M., Blom J., Hansen K., Ostergard S., et al. The dominant epitope of Borrelia garinii outer surface protein C recognized by sera from patients with neuroborreliosis has a surface exposed conserved structural motif. Infect Immun 66 (1998) 4073-4079
25. Jobe D.A., Lovrich S.D., Schell R.F., and Callister S.M. C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. Clin Diagn Lab Immnunol 10 (2003) 573-578
26. Rousselle J.C., Callister S.M., Schell R.F., Lovrich S.D., Jobe D.A., Marks J.A., et al. Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi. J Infect Dis 178 (1998) 733-741
27. Mbow M.L., Gilmore Jr. R.D., and Titus R.G. An OspC-specific monoclonal antibody passively protects mice from tick-transmitted infection by Borrelia burgdorferi B31. Infect Immun 67 October (10) (1999) 5470-5472
28. Probert W.S., Crawford M., Cadiz R.B., and LeFebre R.B. Immunization with outer surface protein (Osp) A but not OspC provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 175 (1997) 400-405
29. Probert W.S., and LeFebvre R.B. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect Immun 62 5 (1994) 1920-1926
30. Seinost G., Dykhuizen D.E., Dattwyler R.J., Golde W.T., Dunn J.J., Wang N., et al. Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect Immun 67 (1999) 3518-3524
31. Wang I.N., Dykhuizen D.E., Qiu W., Dunn J.J., Bosler E.M., and Luft B.J. Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics 151 1 (1999) 15-30
32. Wilske B., Busch U., Fingerle V., Jauris-Heipke S., Preac Mursic V., Rossler D., et al. Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development. Infection 24 2 (1996) 208-212
33. Earnhart C.G., Buckles E.L., Dumler J.S., and Marconi R.T. Demonstration of OspC type diversity in invasive human Lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect Immun 73 12 (2005) 7869-7877
34. Buckles E.L., Earnhart C.G., and Marconi R.T. Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development. Clin Vaccine Immunol 13 10 (2006) 1162-1165
35. Golovanov A.P., Hautbergue G.M., Wilson S.A., and Lian L.Y. A simple method for improving protein solubility and long-term stability. J Am Chem Soc 126 29 (2004) 8933-8939
36. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., et al. Protein identification and analysis tools on the ExPASy server. In: Walker J.M. (Ed). The proteomics protocols handbook (2005), Humana Press, Totowa, NJ 571-608
37. Kumaran D., Eswaramoorthy S., Luft B.J., Koide S., Dunn J.J., Lawson C.L., et al. Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi. EMBO J 20 5 (2001) 971-978
38. Eicken C., Sharma V., Klabunde T., Owens R.T., Pikas D.S., Hook M., et al. Crystal structure of Lyme disease antigen outer surface protein C from Borrelia burgdorferi. J Biol Chem 276 13 (2001) 10010-10015
39. Dale J.B., Chiang E.Y., and Lederer J.W. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol 151 4 (1993) 2188-2194
40. Dale J.B., Simmons M., Chiang E.C., and Chiang E.Y. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine 14 10 (1996) 944-948
41. Dale J.B. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine 17 2 (1999) 193-200
42. Brinckerhoff L.H., Kalashnikov V.V., Thompson L.W., Yamshchikov G.V., Pierce R.A., Galavotti H.S., et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1 (27-35) peptide: implications for peptide vaccines. Int J Cancer 83 3 (1999) 326-334
43. Powell M.F., Grey H., Gaeta F., Sette A., and Colon S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 81 8 (1992) 731-735
44. Lee E.N., Kim Y.M., Lee H.J., Park S.W., Jung H.Y., Lee J.M., et al. Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins. Pharm Res 22 10 (2005) 1735-1746
45. Alvarez P., Buscaglia C.A., and Campetella O. Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences. J Biol Chem 279 5 (2004) 3375-3381
46. Kawarasaki Y., Yamada Y., Ichimori M., Shinbata T., Kohda K., Nakano H., et al. Stabilization of affinity-tagged recombinant protein during/after its production in a cell-free system using wheat-germ extract. J Biosci Bioeng 95 3 (2003) 209-214
47. Walker J.R., Altman R.K., Warren J.W., and Altman E. Using protein-based motifs to stabilize peptides. J Pept Res 62 5 (2003) 214-226
48. Remington S.J., and Breddam K. Carboxypeptidases C and D. Methods Enzymol 244 (1994) 231-248
49. Dale J.B., Penfound T., Chiang E.Y., Long V., Shulman S.T., and Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 12 7 (2005) 833-836
50. Hu M.C., Walls M.A., Stroop S.D., Reddish M.A., Beall B., and Dale J.B. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 70 4 (2002) 2171-2177
51. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41 8 (2005) 1114-1122
52. Dangl J.L., Wensel T.G., Morrison S.L., Stryer L., Herzenberg L.A., and Oi V.T. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 7 7 (1988) 1989-1994
53. Miletic V.D., and Frank M.M. Complement-immunoglobulin interactions. Curr Opin Immunol 7 1 (1995) 41-47
54. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15 4 (2003) 505-514
55. Shibaki A., and Katz S.I. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant. Exp Dermatol 11 2 (2002) 126-134
56. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., and Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163 12 (1999) 6448-6454
57. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 5 (2004) 497-505
58. Petrovsky N., and Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82 5 (2004) 488-496